Intercept Pharma Soars On Liver-Disease Drug Data

By | August 12, 2014

Scalper1 News

Biotech Intercept Pharmaceuticals (ICPT) was riding high on an upgrade and multiple price-target increases after it issued new data late Monday on its fatty-liver-disease drug candidate. Intercept Pharma stock vaulted 31% in early trading on the stock market today, near 346, a four-month high. Monday’s data, which Intercept included in its Q2 financial report, provided more details on the mid-stage clinical trial of obetacholic acid (OCA) for Scalper1 News

Scalper1 News